At present, the company has about 12 molecules that have the potential to be out-licensed and fetch the company substantial revenues over the next two years."We see licensing as a strong affirmation of our innovation-led business strategy and expect to realise even greater licensing revenues in the future," Biocon CMD Kiran Mazumdar-Shaw said. |